TerminatedPhase 2
SONOthrombolysis in Patients With an ST-segment Elevation Myocardial Infarction With fibrinoLYSIS (SONOSTEMI-LYSIS) Trial
Key facts
- Who runs it
- University of Alberta
- Where
- Canada1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 41 people enrolled
- Started
- 23 Feb 2021
- Ended
- 19 Jan 2026
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Definity® with High Mechanical Index Ultrasound
- Record updated
- 4 March 2026
- Why it stopped
- Unlikely to demonstrate the intended benefit within the planned study design and statistical framework.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients presenting with STEMI within 6 hours of symptom onset and:; Are expected to receive reperfusion therapy with fibrinolysis; Have a high-risk STEMI ECG as defined as:; >2mm ST-segment elevation in 2 anterior or lateral leads; or; >2mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of >4mm; Age >30 years; Adequate apical and/or parasternal images by echocardiography
Who cannot take part
- 1. Isolated inferior STEMI without anterior ST-segment depression 2. Previous coronary bypass surgery 3. Cardiogenic shock 4. Known or suspected hypersensitivity to ultrasound contrast agent used for the study 5. Life expectancy of less than two months or terminally ill 6. Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin 7. Known large right to left intracardiac shunts 8. Patient received another investigational medication or treatment within 30 days prior to presentation with STEMI
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will assess the safety and feasibility of sonothrombolysis in the acute management of STEMI undergoing reperfusion therapy with systemic fibrinolysis as part of a pharmacoinvasive approach
The 2 groups in the trial
- SonothrombolysisTreatment being tested
Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity® plus Sonothrombolysis
Treatment: Definity® with High Mechanical Index Ultrasound
- Standard of CareNo study treatment, for comparison
Diagnostic myocardial contrast echocardiography with ultrasound contrast agent 5% Definity®
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Record updated
- 4 March 2026